Fig. 2
From: Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant
Therapeutic efficacy of LNP-pE285K-mAb to treat MC38-p53KO/E285Ktumors. A Schematic representation of the subcutaneous tumor model. Established tumors from MC38-p53KO/E285K cells were treated by intratumoral injection of 40 µg DNA plasmids encoding pE285K-mAb (20 µg each for light-chain and heavy-chain) per tumor 10 days after tumor cell inoculation (n = 5 mice). B Serum levels of E285K-mAb detected using ELISA. C and D FACS analysis of E285K-mAb expression and binding in tumors using anti-hFc mAb. E Tumor volumes in each group were measured at different times after inoculation. The initial tumor size was approximately 50–100 mm3, and treatment with LNP-pE285K-mAb began 10 days after tumor inoculation. F The volumes of each tumor. G Survival rate of the two mouse groups (n = 10 mice). H Proportions of CD19+B, CD3+T, CD4+T, CD8+T, NK, NKT, DCs, Mφ, and Tregs in TILs from the two groups. I and J scRNA-seq of CD45+ immune cells isolated from two groups of tumors, visualized through unified manifold approximation and projection (UMAP). K Identification expression of representative marker genes, such as Ptprc (Cd45) for pan-leukocytes and Cd19 for B cells. L Immune cell subtype changes in tumors treated with LNP-pE285K-mAb. M Comparative analysis of DEGs in immune cells from the two groups. Data were presented as means ± SD. Statistical significance was set at *p < 0.05, **p < 0.01, and ****p < 0.0001; ns, not significant